Stage 3 colon cancer means the cancer has grown into or through the colon wall and spread to nearby lymph nodes, but has not reached distant organs like the liver or lungs. About 37% of colorectal cancers are diagnosed at this regional stage, making it one of the most common presentations. The five-year relative survival rate for regional-stage colorectal cancer is roughly 75%, though individual outcomes vary significantly depending on how deep the tumor has grown and how many lymph nodes are involved.
How Stage 3 Is Defined
Colon cancer staging follows the TNM system: T describes how deep the tumor has penetrated the colon wall, N counts how many nearby lymph nodes contain cancer cells, and M indicates whether cancer has spread to distant sites. Stage 3 is defined by one key feature: cancer is present in at least one regional lymph node (N1 or N2), with no distant spread (M0). The depth of the tumor in the colon wall can range from shallow to full-thickness, but it’s the lymph node involvement that pushes a diagnosis into stage 3.
Substages 3A, 3B, and 3C
Stage 3 is divided into three substages that reflect increasing severity. The differences come down to two variables: how far the tumor extends through the colon wall and how many lymph nodes are affected.
Stage 3A is the least advanced. The tumor has grown into the inner layers of the colon wall (the submucosa or the muscle layer) and has spread to one to three nearby lymph nodes. In some cases, the tumor only reaches the submucosa but has spread to four to six nodes. This substage carries the best prognosis within stage 3.
Stage 3B involves deeper penetration. The tumor has grown through the muscle layer to the outermost layer of the colon (the serosa) or even into the tissue lining the abdominal cavity. Cancer is found in one to three nearby lymph nodes. Alternatively, the tumor reaches the muscle layer or serosa with spread to four to six nodes.
Stage 3C is the most advanced substage. It includes any depth of tumor penetration with cancer found in four or more regional lymph nodes (classified as N2). The number of involved lymph nodes is one of the strongest predictors of outcome in stage 3 disease.
Common Symptoms
Many people with colon cancer have no symptoms in the early stages, and even at stage 3, symptoms can be subtle or easy to dismiss. The most common signs include a noticeable change in bowel habits, such as persistent diarrhea or constipation that doesn’t resolve. Rectal bleeding or blood in the stool is another frequent symptom. Some people experience unexplained weight loss, ongoing abdominal discomfort, or a feeling that the bowel doesn’t empty completely. Symptoms depend partly on where in the large intestine the tumor is located and how large it has grown.
Surgery as the First Step
Treatment for stage 3 colon cancer almost always begins with surgery to remove the section of the colon containing the tumor, along with nearby lymph nodes. Guidelines from several major cancer organizations recommend that the surgeon remove and have a pathologist examine at least 12 lymph nodes. This minimum ensures the cancer is staged accurately, since checking too few nodes could mean missing ones that contain cancer cells. Research has identified having fewer than 17 examined lymph nodes as an independent risk factor for recurrence, suggesting that more thorough lymph node sampling improves both staging accuracy and long-term outcomes.
Chemotherapy After Surgery
After surgery, most stage 3 patients receive chemotherapy to kill any remaining cancer cells and reduce the chance of the cancer returning. Since 2004, the standard approach has been a combination of oxaliplatin with a fluoropyrimidine (given either intravenously or as an oral pill), typically lasting six months.
However, a large international trial involving over 6,000 patients found that three months of the same chemotherapy was non-inferior to six months for many patients. Three-year disease-free survival was nearly identical: 76.7% for the shorter course versus 77.1% for the longer one. The shorter duration came with a meaningful quality-of-life advantage. Peripheral neuropathy, a side effect that causes numbness, tingling, or pain in the hands and feet, affected 58% of patients in the six-month group at moderate-to-severe levels compared to 25% in the three-month group.
In practice, this means your oncologist may recommend three months of chemotherapy if your cancer falls into a lower-risk substage (such as 3A), while six months remains more common for higher-risk cases like 3C. The decision factors in your specific tumor characteristics, overall health, and tolerance for side effects.
Tumor Biology and Treatment Decisions
Not all stage 3 colon cancers behave the same way, even within the same substage. One important biological feature is whether the tumor has a characteristic called microsatellite instability, or MSI. Tumors with this feature have a defect in their DNA repair machinery, which paradoxically tends to make them more responsive to the immune system.
In stage 3, patients with MSI tumors and involvement in one to three lymph nodes (N1) generally have better outcomes than patients whose tumors lack this feature. That advantage narrows for patients with four or more involved nodes (N2). For MSI tumors treated with standard chemotherapy, the strongest predictors of outcome are the depth of tumor invasion and the number of positive lymph nodes. Three-year disease-free survival ranges from about 90% in lower-risk MSI patients down to roughly 65% in higher-risk ones.
Factors That Increase Recurrence Risk
Even after successful surgery and chemotherapy, some stage 3 patients face a higher chance of the cancer coming back. Research has identified three key risk factors for recurrence: bowel obstruction before surgery (meaning the tumor was blocking the intestine), N2 disease (four or more positive lymph nodes), and having fewer lymph nodes examined during surgery. Patients with bowel obstruction had more than five times the odds of recurrence compared to those without it. The number of these risk factors a patient carries clearly stratifies their prognosis, and it also influences how much benefit they get from chemotherapy.
Follow-Up After Treatment
Once surgery and chemotherapy are complete, a structured surveillance schedule begins and continues for at least five years. The goal is to catch any recurrence early, when it’s most treatable.
For the first two years, you can expect physical exams and a blood test measuring a protein called CEA (a tumor marker that can signal recurrence) every three to six months. CT scans of the chest, abdomen, and pelvis are performed every six to twelve months for five years. After the initial two years, physical exams and CEA tests shift to every six months for the next three years.
Colonoscopy follows its own timeline. If you had a complete colonoscopy before surgery, the first follow-up scope is typically one year after the operation. If no precancerous polyps are found, the next one comes three years later, then every five years after that. If a complete colonoscopy wasn’t possible before surgery (sometimes the tumor blocks the scope), one is recommended within three to six months after the operation.
This surveillance period can feel intensive, but each appointment serves a specific purpose. Recurrences caught on routine scans or blood tests, before symptoms develop, are far more likely to be treatable than those found later.